Financiado en parte por Esperion Therapeutics, Esperion Therapeutics Inc
Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis
Kalra DK, Ray KK, Bajaj A, Kushner PR, Wilcox ML, Dicklin MR, Kirkpatrick CF, Maki KC
Journal of clinical lipidology · 10 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Esperion Therapeutics
- Empresa
- Esperion Therapeutics Inc
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-02-14 · J Clin Lipidol · vol. 20 · número 4 · págs. 738–749
- Editorial
- Elsevier BV
- Citado
- 17 citas · más que el 100% de estudios similares · 45.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 41 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cancer, Lipids, and Metabolism · Blood Pressure and Hypertension Studies
- Palabras clave
- LDL cholesterol lowering, major adverse cardiovascular events, primary prevention, statins, bempedoic acid, ezetimibe, relative risk reduction, coronary artery disease, myocardial infarction, stroke, coronary revascularization
- MeSH
- humans, cardiovascular diseases, anticholesteremic agents, hydroxymethylglutaryl-coa reductase inhibitors, risk, risk factors, primary prevention, cholesterol, ldl
8 autores
- Dinesh Kumar Kalra🇺🇸 · autor de correspondenciaUniversity of Louisville
- Kausik Kumar Ray🇬🇧 · autor de correspondenciaImperial College London
- Archna Bajaj🇺🇸 · autor de correspondenciaUniversity of Pennsylvania
- Pamela R. Kushner🇺🇸 · autor de correspondenciaUniversity of California, Irvine Medical Center
- Meredith Leigh Wilcox · autor de correspondencia
- Mary R. Dicklin · autor de correspondencia
- Carol F. Kirkpatrick🇺🇸 · autor de correspondenciaIdaho State University
- Kevin Carl Maki🇺🇸 · autor de correspondenciaIndiana University Bloomington; Indiana University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Analyses of statin trials by the Cholesterol Treatment Trialists' Collaboration have suggested larger relative risk reduction (RRR) for major adverse cardiovascular events (MACE) per 1 mmol/L (38.7 mg/dL) low-density lipoprotein cholesterol (LDL-C) lowering in primary prevention than in secondary prevention. However, controversy remains about the value of LDL-C lowering in primary prevention.
Objective
This meta-analysis examined the relationship between LDL-C reduction and MACE risk in primary prevention with statin and nonstatin LDL-C-lowering therapies in cardiovascular outcomes trials (CVOTs).
Methods
PubMed and Cochrane Central Register of Controlled Trials were searched from inception through August 26, 2025. The primary endpoint was the pooled RRR vs controls for 4-point composite MACE (coronary heart disease death, nonfatal myocardial infarction, fatal and nonfatal stroke, and coronary revascularization) per 1 mmol/L LDL-C lowering.
Results
Eleven CVOTs of solely primary prevention participants (n = 74,466) and 3 in which >80% of participants were primary prevention (n = 24,071) were identified (11 statin, 1 bempedoic acid, 1 ezetimibe, 1 statin+ezetimibe). In 13 trials, the pooled mean difference between groups in LDL-C reduction was 1.00 mmol/L (95% CI: 0.82-1.18 mmol/L) with a pooled estimate of 30% (relative risk: 0.70; 95% CI: 0.67-0.74) RRR for 4-point MACE per 1 mmol/L LDL-C reduction vs control.
Conclusion
In CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated with a 30% RRR in 4-point MACE. These results strengthen the evidence and rationale for the benefits of LDL-C lowering in primary prevention.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.